Aug. 6 at 6:27 PM
$CMMB
Prometheus (Merck –
$10.8 billion, 2023): Their drug (Tulisokibart) targeted the TL1A protein to treat both inflammation and fibrosis. This is the same concept that CM‑101 applies, but in the intestines.
• CymaBay (Gilead –
$4.3 billion, 2024): Their drug Seladelpar was developed to treat a cholestatic liver disease (PBC) that is very similar to PSC. The difference is that CM‑101 is broader, as it addresses cholestasis and directly halts fibrosis.
Conclusion: The mechanism of CM‑101 is not just promising, but it matches the scientific pattern that has already proven its value in multi‑billion‑dollar acquisitions, making it a strategic target for Big Pharma.
